Global Gene Therapy For Inherited Genetic Disorders Market Trends and Future Outlook to 2029
Uncover key drivers, emerging technologies, and competitive movements shaping the gene therapy for inherited genetic disorders market from 2025–2034 with trusted insights from The Business Research Company
What Is The Predicted Market Size Of The Gene Therapy For Inherited Genetic Disorders Industry By 2029?
The gene therapy for inherited genetic disorders market size has seen rapid expansion in recent years. This market is set to increase from $3.39 billion in 2024 to $4.05 billion in 2025, progressing at a compound annual growth rate (CAGR) of 19.4%. Historically, this development can be linked to a rise in government initiatives and supportive policies for gene therapy, enhanced accessibility of advanced gene delivery systems, increasing patient demand for effective and curative treatments, the growing number of clinical trials focused on inherited disorders, and improved awareness among healthcare professionals regarding the advantages of gene therapy.
The gene therapy for inherited genetic disorders market size is projected to experience considerable growth in the coming years, escalating to $8.15 billion by 2029 at a compound annual growth rate (CAGR) of 19.1%. This anticipated expansion during the forecast period is driven by factors such as the increasing prevalence of inherited genetic disorders, growing investment and funding in gene therapy research and development, enhanced awareness and diagnosis rates for rare genetic diseases, rising approvals of novel gene therapy products by regulatory agencies, and the expanding adoption of personalized medicine approaches. Major trends for the forecast period include the integration of advanced delivery systems for targeted gene therapy, continuous developments in viral and non-viral vector technologies, advancements in next-generation sequencing facilitating precise diagnosis, technological improvements in the manufacturing and scalability of gene therapies, and the incorporation of artificial intelligence to optimize gene therapy design.
Get A Free Sample Of The Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=27293&type=smp
Which Factors Are Steering Growth In The Gene Therapy For Inherited Genetic Disorders Market?
The increasing demand for personalized medicine is anticipated to propel the growth of the gene therapy for inherited genetic disorders market moving forward. Personalized medicine involves customizing medical treatments to an individual’s genetic profile and personal characteristics to achieve optimized care. This rise in personalized medicine is largely due to advancements in genetic technologies, which have made tailoring treatments to an individual’s unique genetic makeup both easier and more affordable. Personalized medicine significantly enhances gene therapy by allowing for treatments to be adapted to each patient’s specific genetic profile, ensuring precise gene targeting and delivery while simultaneously improving effectiveness and reducing side effects. For instance, in February 2024, the Personalized Medicine Coalition, a US-based non-profit organization, stated that in 2023, the United States Food and Drug Administration (FDA) gave approval to 16 new personalized treatments for rare disease patients, an increase from six in 2022. The newly approved personalized treatments for 2023 also encompassed seven cancer drugs and three for other diseases and conditions. Therefore, the escalating demand for personalized medicine is a key driver for the growth of the gene therapy for inherited genetic disorders market.
Which Segment Accounts For The Largest Share In The Gene Therapy For Inherited Genetic Disorders Market?
The gene therapy for inherited genetic disorders market covered in this report is segmented
1) By Type: Viral Vector-Based Therapies, Gene Editing Techniques, Ribonucleic Acid-Based Therapies, Ex Vivo Gene Therapy
2) By Application: Inherited Metabolic Disorders, Neurological Disorders, Cardiovascular Disorders, Musculoskeletal Disorders, Ophthalmic Disorders
3) By End-User: Hospitals, Specialty Clinics, Research Institutes, Other End-Users
Subsegments:
1) By Viral Vector-Based Therapies: Adenovirus Vectors, Adeno-Associated Virus (AAV) Vectors, Lentivirus Vectors
2) By Gene Editing Techniques: Zinc Finger Nucleases (ZFNs), Transcription Activator-Like Effector Nucleases (TALENs), Meganucleases
3) By Ribonucleic Acid-Based Therapies: Small Interfering Ribonucleic Acid, Antisense Oligonucleotides (ASOs), Messenger Ribonucleic Acid (mRNA) Therapies
4) By Ex Vivo Gene Therapy: Hematopoietic Stem Cell Gene Therapy, Mesenchymal Stem Cell Gene Therapy, Induced Pluripotent Stem Cell (iPSC) Therapy
Which Long-Term Trends Will Play A Crucial Role In The Gene Therapy For Inherited Genetic Disorders Market?
Major companies within the gene therapy for inherited genetic disorders market are concentrating on advancing solutions, such as establishing gene therapy companies, to devise targeted, safer, and more effective treatments that address the underlying causes of genetic diseases. A gene therapy establishment refers to a biotechnology or pharmaceutical entity specializing in researching, developing, and commercializing gene therapy remedies aimed at correcting or modifying defective genes responsible for inherited genetic disorders. For instance, in November 2022, Replay, a US-based genome writing company, introduced Telaria, a significant DNA HSV gene therapy firm. This company marks the second product company utilizing its high payload capacity herpes simplex virus (HSV) delivery vector, synHSV, and its primary focus is recessive dystrophic epidermolysis bullosa (RDEB), a severe genetic skin condition. The company was co-founded by leading HSV scientists and genetic skin disease experts with the objective of creating transformative gene therapies for these rare skin conditions. This launch follows Replay’s first gene therapy company, Eudora, which targets retinal diseases. Replay’s innovative structure differentiates technology development from therapeutic development by allocating them to distinct product companies focused on specific disease areas.
Who Are The Dominant Players In The Gene Therapy For Inherited Genetic Disorders Market Today?
Major companies operating in the gene therapy for inherited genetic disorders market are Sanofi S.A., Novartis AG, Astellas Pharma Inc., Vertex Pharmaceuticals Incorporated, Genentech, Biomarin Pharmaceutical Inc, Sarepta Therapeutics Inc., Krystal Biotech Inc., Rocket Pharmaceuticals Inc., Sangamo Therapeutics Inc., REGENXBIO Inc., Passage Bio Inc., Voyager Therapeutics Inc., Generation Bio Co., Avrobio Inc, Editas Medicine Inc., MeiraGTx Holdings Plc, uniQure N.V., Intellia Therapeutics Inc., Bluebird Bio Inc, 4D Molecular Therapeutics Inc., CRISPR Therapeutics AG.
Access The Complete Report Here:
What Regional Factors Are Accelerating Growth In The Gene Therapy For Inherited Genetic Disorders Market?
North America was the largest region in the gene therapy for inherited genetic disorders market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gene therapy for inherited genetic disorders market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Customize Your Report Here:
https://www.thebusinessresearchcompany.com/customise?id=27293&type=smp
Browse Through More Reports Similar to the Global Gene Therapy For Inherited Genetic Disorders Market 2025, By The Business Research Company
Asphalt Mixing Plants Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/asphalt-mixing-plants-global-market-report
Asphalt Additives Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/asphalt-additives-global-market-report
Plumbing Fixtures And Fittings Global Market Report 2025
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
